A case of therapy-related acute lymphoblastic leukemia after 131I -treatment for thyroid papillary carcinoma.
- Author:
Tak YOON
1
;
Dae Young KIM
;
Keun Wook LEE
;
Dae Hee KIM
;
Sung Soo YOON
;
Seon Yang PARK
;
Byung Kook KIM
Author Information
1. Department of Internal Medicine, College of Medicine, Seoul National University, Seoul, Korea. ssysmc@snu.ac.kr
- Publication Type:Case Report
- Keywords:
Therapy-Related Neoplasm;
Iodine Radioisotope;
Thyroid Cancer
- MeSH:
Adult;
Bone Marrow Transplantation;
Carcinoma, Papillary*;
Drug Therapy;
Female;
Hematologic Neoplasms;
Humans;
Leukemia, Myeloid, Acute;
Neoplasms, Second Primary;
Precursor Cell Lymphoblastic Leukemia-Lymphoma*;
Prognosis;
Radiotherapy;
Siblings;
Stem Cell Transplantation;
Thyroid Gland*;
Thyroid Neoplasms;
Tissue Donors
- From:Korean Journal of Medicine
2004;66(4):437-441
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
During the last decade the issue of therapy-related myelodysplasia (t-MDS) and acute myeloid leukemia (t-AML) following high-dose chemotherapy (HD-CT) and autologous stem cell transplantation (ASCT) or conventional chemotherapy, radiotherapy for malignant diseases has become increasingly important. The number of patients with hematologic malignancies and chemosensitive or radiosensitive solid tumors undergoing this new type of treatment has expanded dramatically. Recently, we experienced a case of 35-year-old female patient with therapy-related acute lymphoblastic leukemia (t-ALL) after 131I treatment for thyroid papillary carcinoma. Total 131I dose the patient received was 900mCi and patient was diagnosed as having ALL 11 months after last 131I treatment. Although the prognosis of therapy-related acute leukemia/myelodysplastic syndrome is poor, the patient is alive in complete remission after allogeneic bone marrow transplantation from HLA-matched sibling donor. Given the rarity of this case, we report the case with literature reviews.
